These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24130086)

  • 1. Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.
    Suzuki T; Yamauchi T; Ando K; Nagai T; Kakihana K; Miyata Y; Uchida T; Tabata Y; Ogura M
    Jpn J Clin Oncol; 2013 Dec; 43(12):1177-83. PubMed ID: 24130086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
    Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
    Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
    Jeha S; Razzouk B; Rytting M; Rheingold S; Albano E; Kadota R; Luchtman-Jones L; Bomgaars L; Gaynon P; Goldman S; Ritchey K; Arceci R; Altman A; Stine K; Steinherz L; Steinherz P
    J Clin Oncol; 2009 Sep; 27(26):4392-7. PubMed ID: 19652076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.
    Claxton D; Erba HP; Faderl S; Arellano M; Lyons RM; Kovacsovics T; Gabrilove J; Huebner D; Gandhi PJ; Kantarjian H;
    Leuk Lymphoma; 2012 Mar; 53(3):435-40. PubMed ID: 21877883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.
    Jacoby MA; Martin MG; Uy GL; Westervelt P; Dipersio JF; Cashen A; Stockerl-Goldstein K; Vij R; Luo J; Reineck T; Bernabe N; Abboud CN
    Am J Hematol; 2014 May; 89(5):487-92. PubMed ID: 24415560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
    Koh K; Ogawa C; Okamoto Y; Kudo K; Inagaki J; Morimoto T; Mizukami H; Ecstein-Fraisse E; Kikuta A
    Int J Hematol; 2016 Aug; 104(2):245-55. PubMed ID: 27086352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.
    Büttner B; Knoth H; Kramer M; Oertel R; Seeling A; Sockel K; von Bonin M; Stölzel F; Alakel N; Platzbecker U; Röllig C; Ehninger G; Bornhäuser M; Schetelig J; Middeke JM
    Leuk Lymphoma; 2017 Dec; 58(12):2865-2874. PubMed ID: 28509593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clofarabine in the treatment of elderly patients with acute myeloid leukemia.
    Aleem A; Anjum F; Algahtani F; Iqbal Z; Alsaleh K; Almomen A
    Asian Pac J Cancer Prev; 2013; 14(2):1089-92. PubMed ID: 23621192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
    Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
    J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
    Tse E; Leung AY; Sim J; Lee HK; Liu HS; Yip SF; Kwong YL
    Ann Hematol; 2011 Nov; 90(11):1277-81. PubMed ID: 21455604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
    Foster MC; Amin C; Voorhees PM; van Deventer HW; Richards KL; Ivanova A; Whitman J; Chiu WM; Barr ND; Shea T
    Leuk Lymphoma; 2012 Jul; 53(7):1331-7. PubMed ID: 22149206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
    Kantarjian HM; Erba HP; Claxton D; Arellano M; Lyons RM; Kovascovics T; Gabrilove J; Craig M; Douer D; Maris M; Petersdorf S; Shami PJ; Yeager AM; Eckert S; Abichandani R; Faderl S
    J Clin Oncol; 2010 Feb; 28(4):549-55. PubMed ID: 20026805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study.
    Abramson JS; Takvorian RW; Fisher DC; Feng Y; Jacobsen ED; Brown JR; Barnes JA; Neuberg DS; Hochberg EP
    Leuk Lymphoma; 2013 Sep; 54(9):1915-20. PubMed ID: 23289359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
    Löwenberg B; Pabst T; Maertens J; van Norden Y; Biemond BJ; Schouten HC; Spertini O; Vellenga E; Graux C; Havelange V; de Greef GE; de Weerdt O; Legdeur MJ; Kuball J; Kooy MV; Gjertsen BT; Jongen-Lavrencic M; van de Loosdrecht AA; van Lammeren-Venema D; Hodossy B; Breems DA; Chalandon Y; Passweg J; Valk PJ; Manz MG; Ossenkoppele GJ;
    Blood; 2017 Mar; 129(12):1636-1645. PubMed ID: 28049642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
    Zeidan AM; Ricklis RM; Carraway HE; Yun HD; Greer JM; Smith BD; Levis MJ; McDevitt MA; Pratz KW; Showel MM; Gladstone DE; Gore SD; Karp JE
    Br J Haematol; 2012 Jul; 158(2):198-207. PubMed ID: 22594769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
    Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
    Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
    Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
    Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A
    Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.